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Abstract
Background: Markers for longevity that reflect the health condition and predict healthy aging are extremely scarce. Such
markers are, however, valuable in aging research. It has been shown previously that the N-glycosylation pattern of human
immunoglobulin G (IgG) is age-dependent. Here we investigate whether N-linked glycans reflect early features of human
longevity.
Methodology/Principal Findings: The Leiden Longevity Study (LLS) consists of nonagenarian sibling pairs, their offspring,
and partners of the offspring serving as control. IgG subclass specific glycosylation patterns were obtained from 1967
participants in the LLS by MALDI-TOF-MS analysis of tryptic IgG Fc glycopeptides. Several regression strategies were applied
to evaluate the association of IgG glycosylation with age, sex, and longevity. The degree of galactosylation of IgG decreased
with increasing age. For the galactosylated glycoforms the incidence of bisecting GlcNAc increased as a function of age.
Sex-related differences were observed at ages below 60 years. Compared to males, younger females had higher
galactosylation, which decreased stronger with increasing age, resulting in similar galactosylation for both sexes from 60
onwards. In younger participants (,60 years of age), but not in the older age group (.60 years), decreased levels of non-
galactosylated glycoforms containing a bisecting GlcNAc reflected early features of longevity.
Conclusions/Significance: We here describe IgG glycoforms associated with calendar age at all ages and the propensity for
longevity before middle age. As modulation of IgG effector functions has been described for various IgG glycosylation
features, a modulatory effect may be expected for the longevity marker described in this study.
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Introduction
Human aging research would be greatly facilitated if markers
were available that reflect the physiological state of the human
body and predict morbidity and mortality. Such markers indicate
biological age of individuals instead of calendar age, but have so
far hardly been identified [1]. Markers of calendar age have been
described frequently [2].
Among the classes of biomolecules that might reflect mecha-
nisms of biological aging are the sugar chains on proteins and
lipids, which are called glycans. All cells as well as most secreted
proteins carry a set of glycans. These glycans, generated by
enzymatic reactions (not to be confused with non-enzymatic
glycation), play important roles, e.g. in cell-cell interactions, cell-
matrix interactions, molecular trafficking, receptor activation, and
other biological and immunological events [3]. Several classes of
glycans exist, among which the proteoglycans, glycosphingolipid
glycans, O-glycans and N-glycans. In this study we focus on the N-
glycans, which are sugar chains covalently attached to asparagine
residues of proteins. N-glycans all have a common core-structure,
consisting of an N-acetylglucosamine (GlcNAc) attached to the
asparagine, to which a second GlcNAc and three mannoses are
attached. This core may carry a multitude of different glycan
motifs. The biosynthesis of N-glycans is not regulated by a
template, as is the case with proteins, but is mainly dependent on
the expression and activity of specific glycosyltransferases in a cell.
Therefore, a glycoprotein normally exists as a heterogeneous
population of glycoforms which carry different glycans on the
same protein backbone or even the same glycosylation site.
Moreover, shifts in protein glycosylation patterns reflect regulated
modulations of the glycosylation machinery of the different cells
producing that particular glycoprotein.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12566The most common type of N-glycans of plasma proteins is the
complex type. In the biosynthetic route to this N-glycan type,
several GlcNAc transferases attach GlcNAc residues to the
mannoses of the glycan core, which can be further extended by
galactose, sialic acid and fucose residues.
Differences in N-glycosylation patterns of plasma proteins have
been associated with several diseases including rheumatoid
arthritis, malignancies, liver diseases and diabetes [4–7], and it
may be hypothesized that one or more aspects of glycosylation
reflect the overall health status, and could as such constitute
markers for biological age.
Associations of total plasma protein glycosylation patterns with
calendar age have recently been evaluated in a study population of
100 Belgian individuals, subdivided in five sex-matched groups of
20, 30, 40, 50 and 60 years of age [8]. As compared to subjects
of 20 years of age, elderly individuals of ages above 50 had
increased levels of non-galactosylated glycans, while the levels of
galactosylated structures decreased with increasing calendar age.
In the same study, a population of 120 Italian centenarians was
compared to 79 elderly (mean age 81) and 63 middle-aged (mean
age 44) individuals. In this high-age population, changes in plasma
protein glycosylation were observed as a function of age, which
were similar to those observed for the Belgian population. This
indicates that the changes in plasma protein glycosylation with age
can be extrapolated to very high ages. Since long-lived subjects are
considered to show delayed aging, it would be expected that
centenarians reveal glycosylation patterns comparable to younger
age groups; however this was not the case.
A number of studies have also provided evidence that among
the plasma proteins, specifically the glycosylation of immunoglob-
ulins (IgGs) changes with human aging. Parekh et al. reported in
1988 decreased galactosylation of IgG as a function of increasing
age [9]. In subsequent studies the rate of the age-dependent
changes in galactosylation levels of IgG were shown to be sex-
specific [10,11], while also increased levels of glycans with
bisecting GlcNAc were reported to associate with higher age
[10,11]. These results were corroborated in the study with Italian
centenarians [8]. Although the studies mentioned above provided
valuable information regarding changes in glycosylation with
respect to calendar age, the question whether they might reflect
biological age remains open.
Studies into markers for biological age require a specific study
design: nonagenarian sibling pairs, their offspring and partners of
the offspring were recruited in the Leiden Longevity Study (LLS)
[12]. Longevity is a familial trait in these subjects since a 30%
survival advantage over the general population was observed for
the parents of the sibling pairs, the brothers and sisters, and the
offspring. It was recently reported [1] that large LDL cholesterol
particle size is an early hallmark of longevity in this cohort, present
both in the sibling pairs as well as their offspring when compared
to the partners of the offspring as controls.
Here we address the question whether glycosylation of plasma
IgG could likewise be an early hallmark of human longevity. To
this end, we investigated whether previous findings regarding the
relation between galactosylation and calendar age could be
confirmed in participants of the LLS, and subsequently evaluated
whether IgG glycosylation is associated with human familial
longevity.
Results
IgG was isolated from plasma samples of a subset of 1967
participants (1287 offspring of long-lived siblings and 680 partners
of the offspring) of the Leiden Longevity Study (Table 1). Fc
glycosylation patterns of IgG1 and IgG2 were investigated by
analysis of tryptic glycopeptides using MALDI-TOF mass
spectrometry. Six glycoforms per IgG subclass were determined
by MALDI-TOF-MS (Figure 1 and 2). Since the intensities of all
glycoforms were related to the monogalactosylated, core-fucosy-
lated biantennary species (glycoform B), five relative intensities
were registered per IgG subclass.
Associations of IgG glycosylation with calendar age and
sex, and the interaction between sex and calendar age
A large age-range was covered by offspring and partners in the
Leiden Longevity Study (age 30.2–79.2 years), hence we examined
the association of IgG glycosylation with age by linear regression
analysis. The results are shown in Table 2. Clearly, galactosylation
tends to decrease with calendar age as di-galactosylated glycopep-
tides (C and F) are less abundant in older participants, while non-
galactosylated glycopeptides (A and D) are more abundant in older
participants. This is illustrated in Figure 2, where a typical ‘young’
(with low A, D, and high C, F) and a typical ‘old’ (with high A, D,
and low C, F) MALDI-TOF mass spectrum are presented.
Previous publications have shown that sex-specific differences in
IgG glycosylation exist and that the relation between age and IgG
glycosylation is sex-dependent [8,10,11]. Significant differences in
IgG glycosylation were indeed observed between the sexes. For
both IgG1 and IgG2 the glycoforms D and E were more prevalent
in females than in males, while the A and C glycoforms were
respectively more and less prevalent in females, but only for the
IgG2 subclass (Table 2).
Subsequently, we evaluated whether the calendar age-
dependent decrease in galactosylation is sex-specific. Highly
significant interactions between age and sex were observed for
all IgG glycoforms, which is illustrated by the crossing slopes of the
males and females for IgG1 A in Figure 3. Up to 60 years of age,
females tend to have stronger associations between IgG glycosyl-
ation and age than males. From that time point onwards, IgG
glycosylation changes with age are similar for females and males.
To evaluate a possible association of calendar age witha so-called
bisecting GlcNAc, the GlcNAc which is attached to the b-linked
Table 1. Numbers of individuals and average ages of the participants.
Variable Total Offspring Partners of offspring
Total Male Female Total Male Female
Nr. of individuals 1967 1287 635 652 680 289 391
Mean age in Years
(range)
59.22 (30.2–79.2) 59.32(33.6–77.6) 59.50 (33.6–77.6) 59.14 (42.0–76.3) 59.04 (30.2–79.2) 61.53 (30.2–79.2) 57.20 (30.2–74.9)
The mean age, stratified per sex, is depicted.
doi:10.1371/journal.pone.0012566.t001
IgG Glycosylation
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galactosylated and non-galactosylated glycoforms, F/C and D/A
respectively. The resulting regression coefficients are depicted in
Table 2, and the ratios for galactosylated compounds tend to
increase with increasing age. In other words, the relative incidence
of structures with bisecting GlcNAc among the galactosylated
species is increasing with age. This is in accordance with findings by
Yamada et al. and Shikata et al. [10,11]. No interaction between sex
and age was observed for the non-bisecting/bisecting ratio’s,
indicating that the interaction for the non-bisecting glycoform is
similar to the interaction for the bisecting glycoform.
Associations of IgG glycosylation and longevity
The Leiden Longevity Study design allows the testing for
association between glycosylation and familial longevity by
comparing the data of offspring and partners. Logistic regression
analysis performed on the complete dataset did not show
significant differences between these groups. Since the relation
between IgG glycosylation and age differed for females and males
at ages below 60 years (Figure 3), we analyzed the data stratified
for ages below and above 60 years applying logistic regression
analysis. Three glycopeptides, all with bisecting GlcNAc and low
galactosylation, were shown to be lowered in offspring compared
Figure 1. Structures of the N-glycans attached to IgG glycopeptides, as profiled in our analysis. Compositions and structural schemes are
given in terms of N-acetylglucosamine (blue square), mannose (green circle), galactose (yellow circle) and fucose (red triangle).
doi:10.1371/journal.pone.0012566.g001
Figure 2. MALDI-TOF-MS spectra of representatives of a young and an old participant. MALDI-TOF-MS spectra were acquired in the
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in Table 3. Upon further stratification for sex, the associations
between family status and IgG glycosylation were lost, as the
groups were too small.
To further elaborate on the role of structures carrying a
bisecting GlcNAc in familial longevity, logistic regression analysis
was performed on the bisecting/non-bisecting ratios for the
stratified age groups. The results are shown in Table 4. At ages
below 60, the offspring tends to have a lower amount of bisecting
GlcNAc compared to their partners, but only for non-galactosy-
lated glycoforms. This holds for both IgG1 and IgG2. However, as
previously found (Table 3), no differences could be observed above
60 years of age, thus confirming the association of the presence of
a bisecting GlcNAc on non-galactosylated N-glycans from IgG
with familial longevity at younger ages. Since the bisected/non-
bisected ratio for the mono-galactosylated glycans is already
determined in glycoform E due to the normalization on the mono-
galactosylated non-bisected glycoform B, our results indicate that
the presence of a bisecting GlcNAc on non- (Table 3 and 4) and
mono-galactosylated (Table 3) IgG1 as well as non-galactosylated
(Table 3 and 4) IgG2 N-glycans is an early marker for familial
longevity. To illustrate this, the relation between age and IgG
glycosylation is plotted for IgG1 D, stratified for family status, age
group and gender (Figure 4). Clearly, the relative amount of IgG1
D is lowered in the offspring compared to their partners, but only
below 60 years of age.
To evaluate the predictive ability of the association between IgG
glycosylation and longevity, we investigated the areas under the
Table 2. Regression coefficients from the linear regression analysis for the response variable, IgG values, and the covariates age
and sex (female =0, male =1) after adjustment for the family status.
IgG subclass and glycoform Age Sex
change per year of calendar age (SE) P difference between female and male (SE) P
IgG1 A 0.017 (0.001) 0.000
IgG1 C 20.014 (0.001) 0.000
IgG1 D 0.019 (0.001) 0.000 20.033 (0.015) 0.035
IgG1 E 20.036 (0.011) 0.001
IgG1 F 20.009 (0.001) 0.000
IgG2 A 0.019 (0.001) 0.000 20.024 (0.011) 0.035
IgG2 C 20.015 (0.001) 0.000 0.025 (0.010) 0.007
IgG2 D 0.019 (0.001) 0.000 20.081 (0.015) 0.000
IgG2 E 20.051 (0.012) 0.000
IgG2 F 20.006 (0.001) 0.000
IgG1 D/A 20.037 (0.011) 0.001
IgG1 F/C 0.005 (0.001) 0.000
IgG2 D/A 20.058 (0.011) 0.000
IgG2 F/C 0.009 (0.001) 0.000 20.051 (0.017) 0.003
Only significant results (P,0.05) are depicted. Positive regression coefficients for age indicate increased levels with increasing age, while negative coefficients indicate
decreased levels with increasing age. For sex, a positive regression coefficient indicates higher levels for male participants than female participants, while a negative
coefficient indicates lower levels for male participants.
doi:10.1371/journal.pone.0012566.t002
Figure 3. IgG glycosylation and the interaction between age and sex. Relationship between age and IgG1 A glycoform, stratified for sex.
Males are plotted in blue, with a fitted line in dashed dark blue (A), while females are plotted in orange with a fitted line in continuous dark red (B).
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glycoforms. Only subjects younger than 60 years of age were
included. For all three AUC’s values of around 0.6 were obtained,
indicating that multiple markers are needed for the prediction of
complex phenotypes, like familial longevity.
As IgG glycosylation has previously been shown to be associated
with several disease states (e.g. [4–7]) it was assessed whether such
associations could interfere with the observed relationship between
IgG glycosylation and longevity. As most diseases associated with
changes in IgG glycosylation comprise inflammatory components,
the association between glycosylation and levels of C-reactive
protein, a marker for inflammation, was evaluated. While all non-
galactosylated glycoforms were positively associated with levels of
CRP (P,0.001 for all glycoforms), di-galactosylated glycopeptides
(except from IgG2 F) were negatively associated with CRP levels
(P,0.002 for all glycoforms). Upon addition of the CRP level in
the logistic regression model as a covariate, the association between
glycosylation and longevity remained significant (P,0.05), indi-
cating that the association is not affected by individuals carrying an
inflammatory disease.
To further corroborate these results, individuals which had been
diagnosed with malignancies or diabetes, two major age-related
diseases, were excluded from the analysis; this resulted in a
reduction of the cohort size of 28%. The associations between IgG
glycoforms (IgG1 D, IgG1 E and IgG2 D) and longevity remained
significant (P=0.037, P=0.034 and P=0.010, respectively) below
60 years of age. This confirms that the association between IgG
glycosylation and familial longevity is not affected by diseased
individuals.
Discussion
This is the first large-scale study in which IgG glycosylation
patterns have been evaluated for association with familial
longevity and calendar age in one design. Decreased levels of
bisecting GlcNAc in the context of non-galactosylated glycans of
IgG1 and IgG2 were associated with familial longevity in
younger participants (,60 years of age, see Table 3, glycoforms
D). This glycoform was also affected by calendar age (see
Table 2, glycoform D) and since the relative levels of non-
galactosylated glycans containing a bisecting GlcNAc increase
with calendar age, while the offspring is associated with lowered
values, the offspring has a ‘younger’ profile. The offspring was
previously found to be more healthy than their partners [13],
therefore it may be speculated that the non-galactosylated glycan
containing a bisecting GlcNAc is reflecting younger biological
age or better health condition of the offspring as compared to
their partners.
Table 3. Odds ratios and p-values from logistic regression.
IgG subclass and
glycoform Age,60 (n0=372, n1=701) Age.=60 (n0=308, n1=586)
Odds ratio (95% C.I.) P Odds ratio (95% C.I.) P
IgG1 A 0.75 (0.43–1.30) 0.302 0.99 (0.55–1.75) 0.962
IgG1 C 0.85 (0.46–1.58) 0.613 0.91 (0.46–1.80) 0.792
IgG1 D 0.52 (0.34–0.80) 0.003 1.04 (0.66–1.64) 0.882
IgG1 E 0.47 (0.26–0.84) 0.011 1.13 (0.63–2.01) 0.679
IgG1 F 0.68 (0.45–1.03) 0.071 1.03 (0.66–1.61) 0.901
IgG2 A 0.79 (0.45–1.40) 0.425 1.22 (0.68–2.16) 0.506
IgG2 C 0.92 (0.49–1.72) 0.798 0.75 (0.37–1.52) 0.426
IgG2 D 0.53 (0.33–0.83) 0.006 1.10 (0.72–1.70) 0.659
IgG2 E 0.58 (0.32–1.05) 0.071 1.07 (0.64–1.79) 0.806
IgG2 F 0.73 (0.51–1.04) 0.085 1.04 (0.75–1.44) 0.810
Data were split in two groups: one with individuals below 60 years of age, and one with individuals above 60 years of age. 0= partners, 1= offspring. When Odds Ratio
(OR) is reported lower than 1, it indicates that subjects with lower IgG glycosylation values tend to belong to the group of offspring.
doi:10.1371/journal.pone.0012566.t003
Table 4. Logistic regression analysis of non-bisecting/bisecting ratios with the response variable family status.
IgG subclass and ratio Age,60 (n0=372, n1=701) Age.=60 (n0=308, n1=586)
Odds ratio (95% C.I.) p-value Odds ratio (95% C.I.) p-value
IgG1 D/A 0.41 (0.23–0.74) 0.003 1.09 (0.58–2.03) 0.796
IgG1 E
1 0.47 (0.26–0.84) 0.011 1.13 (0.63–2.01) 0.679
IgG1 F/C 0.62 (0.37–1.04) 0.069 1.10 (0.63–1.90) 0.727
IgG2 D/A 0.43 (0.24–0.78) 0.006 0.98 (0.56–1.72) 0.941
IgG2 E
1 0.58 (0.32–1.05) 0.071 1.07 (0.64–1.79) 0.806
IgG2 F/C 0.69 (0.45–1.05) 0.083 1.13 (0.79–1.62) 0.508
Age groups are stratified ,60 and .60. * the value for glycoform E is already a bisecting/non-bisecting ratio as it is normalized on its non-bisected counterform B.
doi:10.1371/journal.pone.0012566.t004
IgG Glycosylation
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bisecting ratio does not associate with calendar age, but again a
decreased ratio for non-galactosylated glycoforms is associated
with the offspring (Table 4, D/A).
In this study, comprising 1967 participants in the age range of
30 to 79 years, a clear tendency of decreased galactosylation with
increasing calendar age was observed (Table 2). This conclusively
confirms earlier data from several other studies on healthy
individuals [8–11]. In one of these studies, Shikata et al. observed
decreased galactosylation with increased age only for female
individuals [10], while, interestingly, we observed this effect for
both sexes. Since female individuals show stronger associations
between calendar age and decreased galactosylation than males up
to 60 years of age, it might be speculated that the cohort studied by
Shikata et al., was only large enough to reveal associations for
female individuals, but not for male individuals.
In addition, a tendency towards increasing levels of bisecting
GlcNAc was observed with increasing age. This could be observed
for both sexes, but only in di-galactosylated glycoforms (Table 2,
F/C). Moreover, we showed for the first time that glycosylation
features of IgG subclasses 1 and 2 have comparable associations
with calendar age, although sex-specific differences were observed
for these subclasses.
As immunoglobulin G is produced in B-lymphocytes, differ-
ences in glycosylation patterns of IgG are postulated to be a
reflection of altered N-glycan biosynthesis in B-lymphocytes. The
decrease in abundance of non-galactosylated glycopeptides
carrying a bisecting GlcNAc with longevity presumably reflects a
Figure 4. IgG glycosylation and its association to longevity. Relationship between age and IgG1 D glycoform, stratified for the family status
and younger/older than 60 years. Values from males are plotted in blue, while values from females are plotted in orange. The fitted lines (dashed dark
blue for males and continuous dark red for females) are drawn using the loess (locally weighted scatter plot smoothing) method.
doi:10.1371/journal.pone.0012566.g004
IgG Glycosylation
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12566decreased activity of GlcNAc transferase III, the enzyme that
catalyzes the addition of a b-1,4-linked GlcNAc to the b-linked
mannose of the trimannosyl core [14], and an increase of the b4-
galactosyltransferase(s), which catalyzes the addition of b-1,4-
linked galactoses to the GlcNAc residues [15,16]. In an alternative,
but less likely explanation the changes could be caused by
alterations in production or location of activated sugar nucleotide
donors. Only non-galactosylated glycoforms containing a bisecting
GlcNAc were shown to be associated with familial longevity, while
the bisecting GlcNAc alone as well as the level of galactosylation
were not associated. The activities of the glycosyltransferases
involved – GlcNAc transferase III and at least one galactosyl-
transferase – might be negatively correlated, possibly by concerted
regulation of transcription of the respective genes.
However, an alternative hypothesis would be that the GlcNAc
transferase III tends to be less active, while, independently, the
galactosyltransferases are more active in offspring versus partners.
All glycopeptides containing a bisecting GlcNAc would then be
decreased with familial longevity and all glycopeptides with
galactoses would be increased with familial longevity. The changes
in glycosylation pattern between the offspring and their partners
are small, therefore significant association could only be found for
the glycans where both effects are changing the levels of a
glycoform in the same direction: the non-galactosylated glyco-
forms containing a bisecting GlcNAc.
Alterations of the glycosylation of the Fc part of IgGs have been
shown to modulate Fc receptor binding. The presence of a
bisecting GlcNAc on an anti-neuroblastoma IgG1 was shown to
increase antibody-dependent cellular cytotoxicity (ADCC) medi-
ated by binding of the antibody to the Fcc-receptor [17], while the
presence of non-fucosylated glycans on the anti-CD-20 IgG1
rituximab was shown to enhance ADCC through its high binding
to both the FccRIIIa-receptor on NK-cells [18] and the FccRIIIb-
receptor on neutrophils [19]. However, in other studies, using
different antibodies, these results could not be confirmed [20],
indicating that it is too early to draw general conclusions about the
influence of glycosylation of IgG on Fc receptor binding and
effector functions. Hence, altered glycosylation as observed in this
study may be expected to modulate IgG effector functions by e.g.
changing the conformation of the Fc part of IgG, thereby
modulating affinity to the Fcc-receptors.
Overall, decreased levels of non-galactosylated glycopeptides
from IgG containing a bisecting GlcNAc were found to be an early
feature of familial longevity detectable at middle age. Moreover,
previous findings on degalactosylation with increasing age could
be corroborated, as well as the sex-specific properties of this
change. To provide a biological basis for these observations, it
would be interesting to study the mechanisms by which protein
glycosylation in B-cells is controlled. Further studies into the gene-
expression of specific glycosylation-related enzymes in B-cells
could also shine light on the biological processes underlying this
association between IgG glycosylation and longevity.
Methods
Participants
In the Leiden Longevity study, Caucasian families were
recruited if at least two long-lived siblings were alive and fulfilled
the age-criterion of 89 years or older for males and 91 year or
older for females, representing less than 0.1% of the Dutch
population in 2001. In total, 956 long-lived proband siblings were
included with a mean age of 94 (89–104), 1750 offspring with a
mean age of 61 (39–81) and 758 partners with a mean age of 60
(36–79) [12].
The study protocol was approved by the Leiden University
Medical Centre Ethical Committee and an informed consent was
signed by all participants prior to participation in the study.
IgG purification and glycosylation analysis
From a subset of the Leiden Longevity Study, consisting of 1287
offspring and 680 partners, immunoglobulin G was purified from
citrate plasma samples in 22 96-wells filter plates using a Protein A
affinity purification step as previously published [21]. In short, 2 ml
of plasma was added to 15 ml Protein A coated beads in 185 ml
PBS in a 96-well plate, and incubated at room temperature for
1 h. After washing, IgGs were eluted using 100 mM formic acid.
After tryptic digestion of the isolated IgGs, peptides were purified
using a C18-SPE plate.
Large scale analysis of IgG glycosylation profiles was performed
using MALDI-TOF-MS. Samples were spotted with a-cyano-4-
hydroxy-cinnamic acid matrix (5 mg/ml in 50% acetonitrile) and
IgG glycosylation patterns were recorded on an Ultraflex II
MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bre-
men, Germany) which was operated in reflectron positive mode.
N=100 shots were acquired per position, and spectra were
acquired from n=20 different positions per spot, resulting in a
sum spectrum obtained by accumulation from 2000 spectra per
sample spot. Calibration was performed on a peptide calibration
standard. The data was baseline subtracted and the intensities of
an identical, defined set of 12 glycopeptide peaks (6 glycoforms for
IgG1 and 6 for IgG2, see Figure 1) were automatically defined for
each spectrum. For all glycoforms, relative intensities were
calculated to the signal intensities of the H4N4F1 (B) glycopeptides
which were set at 100. To evaluate the effect of bisecting GlcNAc,
the ratios between H3N5F1 and H3N4F1 (D/A) and H5N4F1 and
H5N5F1 (F/C) were calculated.
Statistical analyses
To obtain normally distributed variables for IgG glycosylation,
a log transformation was performed on all IgG variables. The
samples of 1967 participants were divided over 22 individual plates
to record IgG glycosylation patterns. Overall batch effects were
assessed by Principal Component Analysis (PCA). Over 79% of
the total variance was explained by the first two principal
components (PCs). Visual inspection of box plots of the individual
PC scores did not indicate heterogeneous within-plates variance,
but mean (or median) values of some plates deviated from other
plates. Therefore, location (mean) batch adjustment was employed
to correct for batch effects [22].
To obtain valid standard errors which take into account familial
correlations, empirical standard errors were calculated. P-values
,0.05 were regarded statistically significant. First, linear regres-
sion was used to explore relationships between each of the
response variables, IgG glycosylation values, and covariates - age
and sex - adjusting for the family status. Next, the inclusion of an
interaction term between sex and age in the linear regression
model produced highly significant results. Further stratification
according to offspring -partner and to young-old showed that the
relationship between age and glycoforms differs for the sex and
offspring-partner combinations and for the sex and young-old
combinations, indicating the presence of three way interactions.
Therefore, we chose a cut-off age of 60 years -which was the mean
age- to create two separate data sets.
To determine potential biomarkers for longevity, logistic
regression was applied to investigate whether IgG glycosylation
value (independent variable) was predictive in classifying the
family status after adjustment for age, sex, and their interaction. In
that respect, the response variable (the family status) is coded as 0
IgG Glycosylation
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12566(= partner) and 1 (= offspring of long-lived sibling). Based on the
interaction study (Figure 3), stratified analyses were conducted
using logistic regression for the family status - adjusting for sex, age
and their interaction: one with individuals younger than 60
(n=1073) and the second with individuals older than 60 years of
age (n=894).
To generate ROC curves, only subjects younger than 60 years
of age were included. First, the effects of age were estimated using
only the partners (as they are not enriched for longevity); the
values for IgG1 D, IgG1 E and IgG2 D were age-adjusted using
these parameters. By fitting the logistic model with binary outcome
(offspring =0, partners =1), and each of the three IgG glycoforms
together with sex as covariates, ROC curves were obtained.
Analyses were performed using STATA 10 (StataCorp LP,
College Station, Texas, USA) and R version 2.9.0 (R Develop-
ment Core Team).
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